Characteristics of pulmonary cryptococcosis in patients with rheumatoid arthritis. 2021

Chiaki Hosoda, and Takashi Ishiguro, and Ryuji Uozumi, and Miyuki Ueda, and Naomi Takata, and Noboru Takayanagi
Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Saitama, Japan ms03hosoda@jikei.ac.jp.

A high frequency of infections complicating rheumatoid arthritis (RA) has been reported due to the immunomodulatory effect of RA or to agents with immunosuppressive effects used in its treatment. We aimed to assess clinical and radiological characteristics of pulmonary cryptococcosis in patients with and without RA. We retrospectively reviewed the medical records of 52 patients with pulmonary cryptococcosis and divided them into two groups, those with RA and without RA, and compared clinical characteristics and radiological findings between them. Eleven (21.2%) of the 52 patients had RA. Median follow-up periods were 51.2 (range: 1.1-258.7) months for patients with RA and 19.1 (range: 0.63-246.9) months for patients without RA. Among the patients with RA, 81.8% were women, with a mean age of 68.1 years. Female sex and respiratory comorbidities were significantly more frequent in patients with RA than in patients without RA. Frequencies of concomitant cryptococcal meningitis and respiratory failure were not different between the groups. There were no significant differences in frequency of any radiological findings, locations and number between the two groups. Among patients with RA, all but one responded well to antifungal treatment. During the antifungal treatment course, one (9.1%) patient with RA died of cryptococcosis. Despite continuing antirheumatic drugs, no patients had recurrence of pulmonary cryptococcosis during follow-up. Other than some differences in background, there were no clinical, radiological or prognostic differences between the patients with and without RA with pulmonary cryptococcosis. The administration of antirheumatic therapy had no negative effect on the clinical course of antifungal treatment.

UI MeSH Term Description Entries
D008172 Lung Diseases, Fungal Pulmonary diseases caused by fungal infections, usually through hematogenous spread. Fungal Lung Diseases,Pulmonary Fungal Infections,Pulmonary Fungal Diseases,Fungal Disease, Pulmonary,Fungal Diseases, Pulmonary,Fungal Infection, Pulmonary,Fungal Infections, Pulmonary,Fungal Lung Disease,Lung Disease, Fungal,Pulmonary Fungal Disease,Pulmonary Fungal Infection
D003453 Cryptococcosis Fungal infection caused by genus CRYPTOCOCCUS. C gattii Infection,C neoformans Infection,C. gattii Infection,C. neoformans Infection,Cryptococcus Infection,Cryptococcus Infections,Cryptococcus gattii Infection,Torulosis,Cryptococcus neoformans Infection,C gattii Infections,C neoformans Infections,C. gattii Infections,C. neoformans Infections,Cryptococcoses,Cryptococcus gattii Infections,Cryptococcus neoformans Infections,Infection, C gattii,Infection, C neoformans,Infection, C. gattii,Infection, C. neoformans,Infection, Cryptococcus,Infection, Cryptococcus gattii,Infection, Cryptococcus neoformans,Infections, C gattii,Infections, C. neoformans,Toruloses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D018501 Antirheumatic Agents Drugs that are used to treat RHEUMATOID ARTHRITIS. Anti-Rheumatic Agent,Anti-Rheumatic Drug,Antirheumatic Agent,Antirheumatic Disease-Modifying Second-Line Drug,Antirheumatic Drug,DMARD,Disease-Modifying Antirheumatic Drug,Disease-Modifying Antirheumatic Drugs,Anti-Rheumatic Agents,Anti-Rheumatic Agents, Non-Steroidal,Anti-Rheumatic Drugs,Antirheumatic Disease-Modifying Second-Line Drugs,Antirheumatic Drugs,Antirheumatic Drugs, Disease-Modifying,Disease-Modifying, Antirheumatic Second-Line Drugs,Agent, Anti-Rheumatic,Agent, Antirheumatic,Anti Rheumatic Agent,Anti Rheumatic Agents,Anti Rheumatic Agents, Non Steroidal,Anti Rheumatic Drug,Anti Rheumatic Drugs,Antirheumatic Disease Modifying Second Line Drug,Antirheumatic Disease Modifying Second Line Drugs,Antirheumatic Drug, Disease-Modifying,Antirheumatic Drugs, Disease Modifying,Disease Modifying Antirheumatic Drug,Disease Modifying Antirheumatic Drugs,Disease Modifying, Antirheumatic Second Line Drugs,Drug, Anti-Rheumatic,Drug, Antirheumatic,Drug, Disease-Modifying Antirheumatic,Non-Steroidal Anti-Rheumatic Agents

Related Publications

Chiaki Hosoda, and Takashi Ishiguro, and Ryuji Uozumi, and Miyuki Ueda, and Naomi Takata, and Noboru Takayanagi
December 2014, Tuberculosis and respiratory diseases,
Chiaki Hosoda, and Takashi Ishiguro, and Ryuji Uozumi, and Miyuki Ueda, and Naomi Takata, and Noboru Takayanagi
November 2013, European journal of radiology,
Chiaki Hosoda, and Takashi Ishiguro, and Ryuji Uozumi, and Miyuki Ueda, and Naomi Takata, and Noboru Takayanagi
September 2020, Tuberkuloz ve toraks,
Chiaki Hosoda, and Takashi Ishiguro, and Ryuji Uozumi, and Miyuki Ueda, and Naomi Takata, and Noboru Takayanagi
January 2004, Clinical imaging,
Chiaki Hosoda, and Takashi Ishiguro, and Ryuji Uozumi, and Miyuki Ueda, and Naomi Takata, and Noboru Takayanagi
February 2023, Internal medicine (Tokyo, Japan),
Chiaki Hosoda, and Takashi Ishiguro, and Ryuji Uozumi, and Miyuki Ueda, and Naomi Takata, and Noboru Takayanagi
December 2009, Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences,
Chiaki Hosoda, and Takashi Ishiguro, and Ryuji Uozumi, and Miyuki Ueda, and Naomi Takata, and Noboru Takayanagi
April 1963, Polski tygodnik lekarski (Warsaw, Poland : 1960),
Chiaki Hosoda, and Takashi Ishiguro, and Ryuji Uozumi, and Miyuki Ueda, and Naomi Takata, and Noboru Takayanagi
January 1982, Scandinavian journal of rheumatology,
Chiaki Hosoda, and Takashi Ishiguro, and Ryuji Uozumi, and Miyuki Ueda, and Naomi Takata, and Noboru Takayanagi
January 1975, Scandinavian journal of respiratory diseases,
Chiaki Hosoda, and Takashi Ishiguro, and Ryuji Uozumi, and Miyuki Ueda, and Naomi Takata, and Noboru Takayanagi
June 2007, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society,
Copied contents to your clipboard!